Key facts
- Naveris’s last known valuation is $81.5M.
- It has raised $85.5M across 3 recorded rounds; the latest was Early Stage VC ($17.5M) in Jun 2024.
- Notable investors include Ms2 Capital, BrightEdge, ABI LAB, American Cancer Society, B-FLEXION Life Sciences — 7 tracked in total.
- Naveris has filed 3 Form Ds with the SEC since 2019, most recently Jul 2024 ($17.5M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Naveris
Funding rounds
3 roundsAbout Naveris
Developer of a blood test technology designed to detect specific cancer subtypes and improve patient outcomes. The company's biomimetic technology replicates the morphological, signaling, and cell lineage complexity of human tissues and tumors ex vivo, enabling patients to get an early diagnosis with real-time monitoring of response and detection of cancer recurrence.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2017
- Employees
- 53
- Website
- naveris.com/
- Ownership
- Privately Held (backing)
Naveris doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Naveris shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Naveris in its N-PORT filings yet. We sweep new filings monthly.